The return of the flu season in India and the US, and COVID-19 in China sparked more investor interest in the sector.
Motilal Oswal recommended Neutral rating on Cipla with a target price of Rs 1180 in its research report dated December 15, 2022.
Sharekhan recommended Hold rating on Cipla with a target price of Rs 1210 in its research report dated December 14, 2022.
Prabhudas Lilladher is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 1300 in its research report dated November 06, 2022.
Motilal Oswal recommended Neutral rating on Cipla with a target price of Rs 1180 in its research report dated November 04, 2022.
Sharekhan is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 1360 in its research report dated November 04, 2022.
ICICI Direct is bullish on Cipla recommended buy rating on the stock with a target price of Rs 1350 in its research report dated November 07, 2022.
Sharekhan is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 1225 in its research report dated September 09, 2022.
Motilal Oswal recommended Neutral rating on Cipla with a target price of Rs 950 in its research report dated August 18, 2022.
Arihant Capital recommended hold rating on Cipla with a target price of Rs 1080 in its research report dated August 01, 2022.
Prabhudas Lilladher is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 1110 in its research report dated August 01, 2022.
Cipla is building its Peptide pipeline with the recently launched Lanreotide injection, which has been well received
ICICI Direct is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 1135 in its research report dated July 30, 2022.
Sharekhan is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 1150 in its research report dated July 29, 2022.
ICICI Direct is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 1095 in its research report dated May 11, 2022.
Motilal Oswal recommended Neutral rating on Cipla with a target price of Rs 880 in its research report dated May 11, 2022.
Prabhudas Lilladher is bullish on Cipla recommended buy rating on the stock with a target price of Rs 1085 in its research report dated May 11, 2022.
Sharekhan is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 1150 in its research report dated May 10, 2022.
Cipla is looking at launching inhalation product Advair in the second half of FY23
Sharekhan is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 1150 in its research report dated March 31, 2022.
KR Choksey recommended accumulate rating on Cipla with a target price of Rs 998 in its research report dated January 28, 2022.
ICICI Direct is bullish on Cipla recommended buy rating on the stock with a target price of Rs 1100 in its research report dated January 26, 2022.
Sharekhan is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 1150 in its research report dated October 26, 2021.
In the US market, while the Albuterol opportunity is stabilising for Cipla, traction for Arformoterol and the high-value product launch calendar in H2 FY23 is a key watch
ICICI Direct is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 1205 in its research report dated August 06, 2021.